Answers are grounded in this paper and cite their sources.
This study introduces a versatile platform for targeted drug delivery that addresses the complexities of conventional immunoliposome preparation. Traditional methods for conjugating a monoclonal antibody (mAb) to the surface of liposomes require target-specific chemical modification for each antibody, frequently resulting in suboptimal ligand orientation, steric hindrance of the antigen-binding sites, and a profound lack of modularity across different targeting systems. We developed Universal Particles (UPs), which are liposomal nanocarriers displaying high-affinity secondary antibodies on their surface. This design enables rapid, non-covalent functionalization by instantly binding to the constant (Fc) region of any whole-molecule primary targeting antibody without the need for chemical modification, thereby promoting a highly accessible, outward-facing display of the antigen-binding domains. In vitro experiments confirmed that UPs successfully functionalized with primary antibodies, leading to specific molecular recognition and enhancing cellular uptake of anti-Muc1/Muc4 UPs by Panc02 pancreatic cancer cells. Analytical flow cytometry confirmed the high expression of these target antigens in the Panc02 line, with 99.5% of cells expressing Muc1 and 99.9% expressing Muc4. In vivo biodistribution studies validated the platform's versatility: αCD31 UPs showed increased accumulation in the lungs, while dual anti-Muc1/Muc4 UPs demonstrated significantly enhanced tumor accumulation in a murine pancreatic tumor model compared with untargeted controls. The UP platform offers a simple approach for antibody-based liposomal targeting, providing a foundation for targeted delivery systems aimed at enhancing therapeutic selectivity and reducing off-target effects in preclinical models.
No takes yet. Share an insight, caveat, or question.
Knani et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: